PEG-Interferon-α ribavirin-induced HCV viral clearance: a pharmacogenetic multicenter Spanish study

• Main Authors: Javier Milara (Author), Maria Outeda-Macias (Author), Mª Dolores Aumente-rubio (Author), Patricio Más-Serrano (Author), Azucena Aldaz (Author), Mª Victoria Calvo (Author), Mª Sergia García-Simón (Author), Marisa Martin-Barbero (Author), Núria Padullés-Zamora (Author), Juan Antonio Schoenenberger (Author), Marianne Saavedra-Aldrich (Author), Enrique Tévar-Alfonso (Author), Ana Saval (Author), Alfonso Pastor-Clerigues (Author), Marta García (Author), Luis Margusino-Framiñan (Author), Jose Luis Montero-Alvarez (Author), Esperanza Merino (Author), Jose Ignacio Herrero (Author), Mónica Beunza (Author), Pablo Conesa-Zamora (Author), Alvaro Gimenez-Manzorro (Author), Dolors Comas-Sugrañes (Author), Manuel Cano-Marron (Author), Elena Jiménez-Mutiloa (Author), Pilar Díaz-Ruíz (Author), Julio Cortijo (Author)
• Format: Book
• Published: Elsevier, 2015-01-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Objective: Dual PEGylated interferon-(PEG-IFN) and ribavirin therapy has been the main hepatitis C virus (HCV) treatment of the last decade. Current direct-acting antiviral agents have improved the outcome of therapy but also have increased the cost and management complexity of treatment. The curr...